UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Mcl-1 antagonism is a potential therapeutic strategy in a subset of solid cancers

Experimental cell research, 2015-03, Vol.332 (2), p.267-277

2015

Volltextzugriff (PDF)

Entrectinib, a Pan-TRK, ROS1, and ALK Inhibitor with Activity in Multiple Molecularly Defined Cancer Indications

Molecular cancer therapeutics, 2016-04, Vol.15 (4), p.628-639

2016

Volltextzugriff (PDF)

Sensitivity to Entrectinib Associated With a Novel LMNA-NTRK1 Gene Fusion in Metastatic Colorectal Cancer

JNCI : Journal of the National Cancer Institute, 2016-01, Vol.108 (1), p.1

2016

Volltextzugriff (PDF)

Italia settentrionale: crocevia di idiomi romanzi: Atti del convegno internazionale di studi. Trento, 21-23 ottobre 1993

Emanuele Banfi, Giovanni Bonfadini, Patrizia Cordin, Maria Iliescu, Emanuele Banfi, Giovanni Bonfadini, Patrizia Cordin, Maria Iliescu

Reprint 2010., 2011

Volltextzugriff (PDF)

Abstract 4785: NMS-E668, a highly potent orally available RET inhibitor with selectivity towards VEGFR2 and demonstrated antitumor efficacy in multiple RET-driven cancer models

Cancer research (Chicago, Ill.), 2018-07, Vol.78 (13_Supplement), p.4785-4785

2018

Volltextzugriff (PDF)

Abstract 1615: NMS-812, a novel potent PERK inhibitor that also inhibits GCN2, exhibits strong anti-tumor activity as single agent and in combination in preclinical models

Cancer research (Chicago, Ill.), 2023-04, Vol.83 (7_Supplement), p.1615-1615

2023

Volltextzugriff (PDF)

Abstract 2082: NMS-E668, a potent and selective RET kinase inhibitor characterized by specificity towards VEGFR2 and high antitumor efficacy against RET-driven models

Cancer research (Chicago, Ill.), 2017-07, Vol.77 (13_Supplement), p.2082-2082

2017

Volltextzugriff (PDF)

Abstract 5163: Characterization of NMS-E194, a selective and potent PERK inhibitor with efficacy in the KMS-11 multiple myeloma

Cancer research (Chicago, Ill.), 2017-07, Vol.77 (13_Supplement), p.5163-5163

2017

Volltextzugriff (PDF)

Identification of a phenylacylsulfonamide series of dual Bcl-2/Bcl-xL antagonists

Bioorganic & medicinal chemistry letters, 2012-06, Vol.22 (12), p.3946-3950

2012

Volltextzugriff (PDF)

Structure-based optimization of potent PDK1 inhibitors

Bioorganic & medicinal chemistry letters, 2010-07, Vol.20 (14), p.4095-4099

2010

Volltextzugriff (PDF)

Abstract 2092: The ALK inhibitor NMS-E628 also potently inhibits ROS1 and induces tumor regression in ROS-driven models

Cancer research (Chicago, Ill.), 2013-04, Vol.73 (8_Supplement), p.2092-2092

2013

Volltextzugriff (PDF)

Abstract 2091: Identification of a highly potent, selective and orally available RET inhibitor with antitumor efficacy in RET-dependent tumor models

Cancer research (Chicago, Ill.), 2013-04, Vol.73 (8_Supplement), p.2091-2091

2013

Volltextzugriff (PDF)

Pyrazole and pyrimidine phenylacylsulfonamides as dual Bcl-2/Bcl-xL antagonists

Bioorganic & medicinal chemistry letters, 2012-06, Vol.22 (12), p.3951-3956

2012

Volltextzugriff (PDF)

Abstract A232: In vitro and in vivo activity of NMS-E628 against ALK mutations resistant to Xalkori

Molecular cancer therapeutics, 2011-11, Vol.10 (11_Supplement), p.A232-A232

2011

Volltextzugriff (PDF)

Effect of protein kinase C inhibitors on invasiveness of human melanoma clones expressing different levels of protein kinase C isoenzymes

International journal of cancer, 1994-04, Vol.57 (2), p.281-286

1994

Volltextzugriff (PDF)

The daunorubicin-binding protein of Mr 54,000 is an aldehyde dehydrogenase and is down-regulated in mouse liver tumors and in tumor cell lines

Molecular pharmacology, 1994-11, Vol.46 (5), p.896-900

1994

Volltextzugriff (PDF)

Synthesis of Alkyl Chain-Modified Ether Lipids and Evaluation of Their in Vitro Cytotoxicity

Journal of medicinal chemistry, 1995-03, Vol.38 (7), p.1216-1228

1995

Volltextzugriff (PDF)

Protein kinase C activation by anthracyclines in swiss 3T3 cells

International journal of cancer, 1991-01, Vol.47 (1), p.136-142

1991

Volltextzugriff (PDF)

Protein kinase C activation and lipid peroxidation by doxorubicin analogues

Tumori, 1989-08, Vol.75 (4), p.358-361

1989

Volltextzugriff (PDF)

Hypocalcemia in COVID-19 is associated with low vitamin D levels and impaired compensatory PTH response

Endocrine, 2021-11, Vol.74 (2), p.219-225

2021

Volltextzugriff (PDF)

The Central Role of Iron in Human Nutrition: From Folk to Contemporary Medicine

Nutrients, 2020-06, Vol.12 (6), p.1761

2020

Volltextzugriff (PDF)

Prenylcysteine Oxidase 1 (PCYOX1), a New Player in Thrombosis

International journal of molecular sciences, 2022-03, Vol.23 (5), p.2831

2022

Volltextzugriff (PDF)

1 – 25 von 139

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(99)
Mit Volltextzugriff
(127)

Publikationsform

Sprache

Englisch
(105)
Italienisch
(34)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Discovery of Entrectinib: A New 3‑Aminoindazole As a Potent Anaplastic Lymphoma Kinase (ALK), c‑ros Oncogene 1 Kinase (ROS1), and Pan-Tropomyosin Receptor Kinases (Pan-TRKs) inhibitor

Mcl-1 antagonism is a potential therapeutic strategy in a subset of solid cancers

Entrectinib, a Pan-TRK, ROS1, and ALK Inhibitor with Activity in Multiple Molecularly Defined Cancer Indications

Sensitivity to Entrectinib Associated With a Novel LMNA-NTRK1 Gene Fusion in Metastatic Colorectal Cancer

Italia settentrionale: crocevia di idiomi romanzi: Atti del convegno internazionale di studi. Trento, 21-23 ottobre 1993

The TPM3-NTRK1 rearrangement is a recurring event in colorectal carcinoma and is associated with tumor sensitivity to TRKA kinase inhibition

Abstract 4785: NMS-E668, a highly potent orally available RET inhibitor with selectivity towards VEGFR2 and demonstrated antitumor efficacy in multiple RET-driven cancer models

Correction to Discovery of Entrectinib: A New 3‑Aminoindazole as a Potent Anaplastic Lymphoma Kinase (ALK), c‑ros Oncogene 1 Kinase (ROS1), and Pan-Tropomyosin Receptor Kinases (Pan-TRKs) inhibitor

Abstract 1615: NMS-812, a novel potent PERK inhibitor that also inhibits GCN2, exhibits strong anti-tumor activity as single agent and in combination in preclinical models

Abstract 2082: NMS-E668, a potent and selective RET kinase inhibitor characterized by specificity towards VEGFR2 and high antitumor efficacy against RET-driven models

Abstract 5163: Characterization of NMS-E194, a selective and potent PERK inhibitor with efficacy in the KMS-11 multiple myeloma

Identification of a phenylacylsulfonamide series of dual Bcl-2/Bcl-xL antagonists

Structure-based optimization of potent PDK1 inhibitors

Abstract 2092: The ALK inhibitor NMS-E628 also potently inhibits ROS1 and induces tumor regression in ROS-driven models

Abstract 2091: Identification of a highly potent, selective and orally available RET inhibitor with antitumor efficacy in RET-dependent tumor models

Pyrazole and pyrimidine phenylacylsulfonamides as dual Bcl-2/Bcl-xL antagonists

Abstract A232: In vitro and in vivo activity of NMS-E628 against ALK mutations resistant to Xalkori

Effect of protein kinase C inhibitors on invasiveness of human melanoma clones expressing different levels of protein kinase C isoenzymes

The daunorubicin-binding protein of Mr 54,000 is an aldehyde dehydrogenase and is down-regulated in mouse liver tumors and in tumor cell lines

Synthesis of Alkyl Chain-Modified Ether Lipids and Evaluation of Their in Vitro Cytotoxicity

Protein kinase C activation by anthracyclines in swiss 3T3 cells

Protein kinase C activation and lipid peroxidation by doxorubicin analogues

Hypocalcemia in COVID-19 is associated with low vitamin D levels and impaired compensatory PTH response

The Central Role of Iron in Human Nutrition: From Folk to Contemporary Medicine

Prenylcysteine Oxidase 1 (PCYOX1), a New Player in Thrombosis

Suchergebnisse filtern